Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026)
Harrow's (HROW) quarterly Net Income towards Common Stockholders came in at -$27.6 million in Q1 2026, down 55.24% year-on-year from -$61.7 million in Q1 2025, and down 365.48% quarter-over-quarter from $10.4 million in Q4 2025.
Harrow (HROW) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Harrow's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$27.6 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 55.24% year-over-year to -$27.6 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 48.42% increase from a year earlier, with the FY2025 full-year figure at -$5.1 million, up 70.6% from the prior year.
- Net Income towards Common Stockholders fell to -$27.6 million in Q1 2026 per HROW's latest filing, from $10.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.4 million in Q4 2025 and bottomed at -$27.6 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$4.4 million (2023), against an average of -$5.0 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 1223.5% in 2022 and surged 177.17% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $1.1 million in 2022, then plunged by 967.11% to -$9.1 million in 2023, then surged by 174.08% to $6.8 million in 2024, then surged by 53.42% to $10.4 million in 2025, then plunged by 365.48% to -$27.6 million in 2026.
- Per Business Quant, the three latest HROW Net Income towards Common Stockholders figures stand at -$27.6 million (Q1 2026), $10.4 million (Q4 2025), and $1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn | -27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.42 Mn |
| Sep 30, 2021 | -8.33 Mn |
| Jun 30, 2021 | -2.95 Mn |